Beacon Harbor Wealth Advisors Inc. Increases Stock Position in Johnson & Johnson (NYSE:JNJ)

Beacon Harbor Wealth Advisors Inc. grew its stake in Johnson & Johnson (NYSE:JNJ) by 0.4% during the third quarter, according to its most recent 13F filing with the SEC. The firm owned 47,498 shares of the company’s stock after acquiring an additional 175 shares during the period. Johnson & Johnson comprises 1.8% of Beacon Harbor Wealth Advisors Inc.’s investment portfolio, making the stock its 15th biggest holding. Beacon Harbor Wealth Advisors Inc.’s holdings in Johnson & Johnson were worth $7,698,000 as of its most recent filing with the SEC.

Several other large investors have also recently made changes to their positions in JNJ. Meridian Financial Partners LLC purchased a new position in shares of Johnson & Johnson in the second quarter valued at approximately $1,626,000. Franklin Parlapiano Turner & Welch LLC boosted its position in Johnson & Johnson by 0.7% in the 1st quarter. Franklin Parlapiano Turner & Welch LLC now owns 47,186 shares of the company’s stock valued at $7,464,000 after buying an additional 325 shares during the period. Lmcg Investments LLC grew its stake in shares of Johnson & Johnson by 32.7% in the third quarter. Lmcg Investments LLC now owns 87,162 shares of the company’s stock worth $14,125,000 after acquiring an additional 21,471 shares in the last quarter. NTV Asset Management LLC increased its position in shares of Johnson & Johnson by 1.6% during the first quarter. NTV Asset Management LLC now owns 36,000 shares of the company’s stock worth $5,695,000 after acquiring an additional 565 shares during the period. Finally, Cooper Haims Advisors LLC raised its stake in shares of Johnson & Johnson by 6.4% in the first quarter. Cooper Haims Advisors LLC now owns 3,358 shares of the company’s stock valued at $531,000 after acquiring an additional 201 shares in the last quarter. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, VP Robert J. Decker sold 5,635 shares of the business’s stock in a transaction on Friday, August 30th. The stock was sold at an average price of $165.06, for a total value of $930,113.10. Following the completion of the transaction, the vice president now directly owns 18,973 shares of the company’s stock, valued at $3,131,683.38. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Insiders own 0.16% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on JNJ. Royal Bank of Canada upped their price target on Johnson & Johnson from $178.00 to $181.00 and gave the stock an “outperform” rating in a report on Wednesday, October 16th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $215.00 target price on shares of Johnson & Johnson in a report on Wednesday, October 16th. The Goldman Sachs Group lowered their price target on shares of Johnson & Johnson from $160.00 to $155.00 and set a “neutral” rating for the company in a report on Friday, July 19th. Wells Fargo & Company raised their price objective on shares of Johnson & Johnson from $163.00 to $166.00 and gave the company an “equal weight” rating in a report on Wednesday, October 16th. Finally, Guggenheim upped their price objective on Johnson & Johnson from $156.00 to $162.00 and gave the stock a “neutral” rating in a research report on Wednesday. Seven investment analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, Johnson & Johnson has an average rating of “Moderate Buy” and a consensus target price of $175.00.

Johnson & Johnson Trading Down 0.7 %

Shares of Johnson & Johnson stock opened at $156.71 on Friday. Johnson & Johnson has a 1 year low of $143.13 and a 1 year high of $168.85. The company has a market capitalization of $377.30 billion, a P/E ratio of 22.68, a PEG ratio of 2.81 and a beta of 0.53. The company’s fifty day moving average is $162.96 and its two-hundred day moving average is $155.76. The company has a debt-to-equity ratio of 0.45, a quick ratio of 0.79 and a current ratio of 1.03.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Tuesday, October 15th. The company reported $2.42 earnings per share for the quarter, topping analysts’ consensus estimates of $2.21 by $0.21. The company had revenue of $22.47 billion during the quarter, compared to analysts’ expectations of $22.17 billion. Johnson & Johnson had a return on equity of 35.45% and a net margin of 19.14%. The firm’s revenue for the quarter was up 5.2% on a year-over-year basis. During the same period last year, the firm earned $2.66 EPS. Analysts forecast that Johnson & Johnson will post 9.94 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 10th. Stockholders of record on Tuesday, November 26th will be given a $1.24 dividend. The ex-dividend date is Tuesday, November 26th. This represents a $4.96 annualized dividend and a dividend yield of 3.17%. Johnson & Johnson’s dividend payout ratio is presently 71.78%.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.